Drug Information Handbook 2012-2013

Author:
Edition: 21
Publisher: Lexi Comp
Binding: Paperback
ISBN: 1591953073

Drug Information Handbook 2012-2013: A Comprehensive Resource for All Clinicians and Healthcare Professionals

We proudly present the "Drug Information Handbook, 21st Edition", continuing Lexicomp's tradition of delivering trusted, pharma-free pharmacotherapy knowledge to healthcare professionals. Medical books Drug Information Handbook 2012-2013. As always, this resource follows a user-friendly, dictionary-like format, providing clinicians with fast access to Lexicomp's clear, concise drug information. Endorsed by the American Pharmacists Association (APhA), Lexicomp's "Drug Information Handbook" is relied on daily by clinicians everywhere to improve medication safety and enhance patient care. Benefits Lexicomp's "Drug Information Handbook, 20th Edition", covers over 5,500 medications and features 31 new monographs and hundreds of updates to existing content. Each monograph encompasses up to 37 fields of information, including detailed content on dosage, drug interactions and adverse reactions Medical books Drug Information Handbook 2012-2013. Drug Information Handbook 2012-2013

Download link for Drug Information Handbook 2012-2013 - Lexi-comp Inc. (cor)

Drug Information Handbook 2012-2013

Drug Information Handbook 2012-2013 LEXCM 9781591953074 09781591953074

New Paperback.

Contributors: Lexicomp - Author. Format: Paperback

Medical Book Drug Information Handbook 2012-2013

As always, this resource follows a user-friendly, dictionary-like format, providing clinicians with fast access to Lexicomp's clear, concise drug information. Endorsed by the American Pharmacists Association (APhA), Lexicomp's "Drug Information Handbook" is relied on daily by clinicians everywhere to improve medication safety and enhance patient care. Benefits Lexicomp's "Drug Information Handbook, 20th Edition", covers over 5,500 medications and features 31 new monographs and hundreds of updates to existing content. Each monograph encompasses up to 37 fields of information, including detailed content on dosage, drug interactions and adverse reactions. Supplementing Lexicomp's drug information is a comprehensive Appendix offering charts, tables, treatment guidelines and therapy recommendations and a Pharmacologic Category Index listing all drugs within their unique pharmacologic class.

PAREXEL Biopharmaceutical Statistical Sourcebook 2012/2013 pdf

Author: PAREXEL International
Edition: 1
Publisher: Parexel Intl Corp
Binding: Hardcover
ISBN: 1882615972

PAREXEL Biopharmaceutical Statistical Sourcebook 2012/2013 (Pharmaceutical R & D Statistical Sourcebook)

The PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013 is the leading resource for statistics, trends, and proprietary market intelligence and analysis on the biopharmaceutical industry. Medical books PAREXEL Biopharmaceutical Statistical Sourcebook 2012/2013 . Supported by thousands of graphs, illustrations, and analysis, the Sourcebook provides the latest market intelligence on every aspect of biopharmaceutical development from product discovery, to R&D performance and productivity, to time-to-market trends. With key analysis and contributions from leading consultancies and experts, the Sourcebook provides real-world data and analysis, including: * A record number of all-new metrics on drug development costs and complexity. * New proprietary analyses on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials. * Emerging data on worldwide and company-specific R&D pipelines, strategies, and product launch trends Medical books .

Download link for Parexel Biopharmaceutical Statistical Sourcebook 2012/2013

Medical Book PAREXEL Biopharmaceutical Statistical Sourcebook 2012/2013

Supported by thousands of graphs, illustrations, and analysis, the Sourcebook provides the latest market intelligence on every aspect of biopharmaceutical development from product discovery, to R&D performance and productivity, to time-to-market trends. With key analysis and contributions from leading consultancies and experts, the Sourcebook provides real-world data and analysis, including: * A record number of all-new metrics on drug development costs and complexity. * New proprietary analyses on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials. * Emerging data on worldwide and company-specific R&D pipelines, strategies, and product launch trends. * New analyses on emerging trends in pharma and biotech licensing deals and other partnerships critical to industry's efforts. * Drug approval statistics compiled from FDA, EMEA, and other regulatory agencies. * New global R&D spending trends and other international R&D data from key markets. * International statistics on drug development output. * And much more! Plus, NEW in the 2012/2013 edition: * An all-new 2012 analysis on the current share of clinical trial spending by region for 2011. * All-new studies on the emerging clinical trial markets in India, China, Korea, Canada, and dozens of other key markets and regions. * All-new analyses and actual/projected metrics on the biosimilars market. * A series of new "dashboards" on costs by phase of development, R&D attrition rates, product development times, and other areas. * Forecasting models on biopharma sales, R&D spending, the pharma/biotech markets, and other meaningful industry metrics. The PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013 is a must-have resource for the drug development industry. It is an invaluable resource for executives and managers working in the pharma and biotech industries. The Sourcebook puts real-world data sets at your fingertips for presentations, reports, business development efforts, strategic meetings, and critical decision-making analyses.